vVARDIS Holding AG is a healthcare company based in Switzerland, founded by Dr. Haley Abivardi and Dr. Goly Abivardi, focused on revolutionizing oral health. The company has developed a clinically validated technology platform, Curodont®, which offers non-invasive treatments for early-stage cavities. Curodont® aims to address a large global healthcare need by preserving tooth structure and enhancing enamel density using proprietary peptide-enabled formulations. Their flagship products include Curodont® Repair Fluoride Plus, mainly sold in the U.S., contributing significantly to their revenue. The company has treated an estimated three-and-a-half million teeth and sold products to over 20,000 dental practices in the U.S. by mid-2026. vVARDIS estimates the addressable market for early-stage cavities in the U.S. to be around $29 billion, highlighting their innovative approach in a long-standing sector.
The company generates revenue primarily from the sales of its flagship products, Curodont® Repair Fluoride Plus and Curodont® Repair. Curodont® Repair Fluoride Plus is sold as an over-the-counter drug regulated by the FDA, which does not evaluate its safety or efficacy. Revenue figures indicate significant growth in net revenue and gross profit, reflecting a strong market adoption of their products.
Not disclosed in the provided filing text.
This summary is generated automatically from the company's own filing and may contain errors or omissions. It is a reading aid, not a substitute for the filing itself, and it is not advice.
The expected date is Nov 9, 2026. Underwriters on the deal include Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, William Blair & Company, L.L.C, UBS Securities LLC, Deutsche Bank Securities Inc, Apollo Global Securities, LLC. vVARDIS Holding AG is headquartered in Switzerland. It is classified under Surgical & Medical Instruments & Apparatus.
Other IPOs DiscoverIPO tracks that share a sector, market, or underwriter with vVARDIS Holding AG.
Drop a live deal card into your own site — works in WordPress, Ghost, Notion, Webflow, and any self-hosted page that allows an <iframe>. It does not work in Substack or in an emailed newsletter — no email client, and Substack itself, supports arbitrary iframes. For those, use the share image or the attribution text below instead.
<iframe src="https://www.discoveripo.com/embed/vvardis" width="100%" height="300" style="border:0;max-width:560px" loading="lazy" title="vVARDIS Holding AG — DiscoverIPO"></iframe>
Dark by default. For a light background, use https://www.discoveripo.com/embed/vvardis?theme=light as the src instead.
https://www.discoveripo.com/ipo/vvardis/opengraph-image
vVARDIS Holding AG IPO details — tracked by DiscoverIPO: https://www.discoveripo.com/ipo/vvardis?utm_source=embed&utm_medium=text&utm_campaign=vvardis
Get emailed when vVARDIS Holding AG's terms, price, or expected date change — no weekly noise, just this company.
vVARDIS Holding AG is expected to list on Nov 9, 2026.
Registration statement filed with the U.S. Securities and Exchange Commission. Retrieved Nov 6, 2026.
View the original filing on SEC EDGAR →Not investment advice. DiscoverIPO is an informational database. Nothing here is a recommendation to buy or sell any security, and no content should be relied on as financial advice. All figures come from public securities-regulator filings, may be incomplete or out of date, and should be verified against the original source before you act on them.
We use analytics and marketing cookies to understand traffic and improve the site. Cookie Policy